What is Agenus?
Agenus is a clinical-stage biopharmaceutical company dedicated to the discovery and development of immuno-oncology products, including checkpoint antibodies, cell therapies, and vaccines. Central to its operational strategy is the Retrocyte Display platform, a proprietary engine designed to generate fully human therapeutic antibody drug candidates. By focusing on the intersection of immunology and oncology, Agenus aims to address significant unmet medical needs through precision medicine and advanced biological engineering. The company's market position is defined by its ability to translate complex scientific research into viable clinical assets, supported by a diverse portfolio of intellectual property and strategic partnerships within the life sciences industry.
How much funding has Agenus raised?
Agenus has raised a total of $547.1M across 9 funding rounds:
Share Placement
$10M
Debt
$5M
Debt
$21.1M
Debt
$100M
Share Placement
$60M
Debt
$230M
Debt
$1M
Private Equity
$35M
Stock/Share Issuance
$85M
Share Placement (2009): $10M with participation from Hudson Capital Group, Iroquois Capital, and Downsview Capital
Debt (2013): $5M, investors not publicly disclosed
Debt (2015): $21.1M, investors not publicly disclosed
Debt (2015): $100M, investors not publicly disclosed
Share Placement (2017): $60M backed by Incyte
Debt (2018): $230M with participation from HealthCare Royalty Partners
Debt (2020): $1M led by PPP
Private Equity (2020): $35M supported by Betta Pharmaceuticals Co., Ltd.
Stock/Share Issuance (2026): $85M featuring RA Capital Management, Ligand Pharmaceuticals, TCG Crossover, Commodore Capital, and Invus
Key Investors in Agenus
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics.
Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on developing and acquiring technologies to assist other pharmaceutical firms in the discovery and development of medicines worldwide.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and investing in breakthrough therapies that have the potential to transform healthcare.
What's next for Agenus?
With the successful closure of this major strategic investment, Agenus is well-positioned to advance its lead programs through critical clinical milestones. The company's forward-looking strategy centers on the maturation of its pipeline and the potential commercialization of its next-generation immunotherapies. Investors and stakeholders are closely monitoring the firm's ability to convert its research-heavy model into sustainable clinical outcomes. Moving forward, Agenus will likely prioritize the optimization of its discovery engine and the expansion of its collaborative network to maintain its trajectory as a leader in the development of transformative cancer treatments.
See full Agenus company page
